Compare JBSS & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBSS | SDGR |
|---|---|---|
| Founded | 1959 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.0M | 925.8M |
| IPO Year | 1994 | 2020 |
| Metric | JBSS | SDGR |
|---|---|---|
| Price | $75.77 | $12.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $109.00 | $21.00 |
| AVG Volume (30 Days) | 90.9K | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $1,107,246,000.00 | $255,869,000.00 |
| Revenue This Year | $5.58 | $0.76 |
| Revenue Next Year | N/A | $4.60 |
| P/E Ratio | $16.75 | ★ N/A |
| Revenue Growth | 3.79 | ★ 23.29 |
| 52 Week Low | $59.07 | $10.95 |
| 52 Week High | $85.15 | $27.63 |
| Indicator | JBSS | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 53.57 |
| Support Level | $74.24 | $11.18 |
| Resistance Level | $84.04 | $13.36 |
| Average True Range (ATR) | 3.16 | 0.67 |
| MACD | -0.58 | 0.03 |
| Stochastic Oscillator | 3.75 | 59.89 |
John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.